Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancers receiving moderately emetogenic chemotherapy regimens

Autor: Weinstein, C., Jordan, K., Green, S., Khanani, S., Beckford-Brathwaite, E., Vallejos, W., Pong, A., Noga, S.J., Rapoport, B.L.
Zdroj: In Gynecologic Oncology June 2018 149 Supplement 1:161-162
Databáze: ScienceDirect